ArticleOpen forum infectious diseases2026
Protective Human Papillomavirus Type 16/18 Vaccine-Induced Neutralizing Antibody Levels Remain Elusive.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We studied human papillomavirus antibodies in a subset of a cohort comprising 16 988 women who received human papillomavirus (HPV) 16/18 vaccination as adolescents, among whom 50 cervical high-grade squamous cell intraepithelial lesions (HSILs) were diagnosed by 28 years of age. No differences in neutralizing HPV16/18 antibody levels between the HSIL cases and 1:2 matched vaccinated controls with or without persistent cervical HPV infection were observed. As compared with the HPV16/18, cross-neutralizing HPV33 antibody levels were significantly increased in the HSIL cases with concomitant cervical and serum sampling. However, during 16 years of follow-up, protective vaccine-induced, HPV16/18 cross-neutralizing (clade A9/A7 specific) antibody levels remained elusive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.